Prolepsia forecastYes / no

Will the UK Competition and Markets Authority open more than 5 Phase 2 merger reviews in 2027?

As of 16 November 2026, Prolepsia puts the chance of yes at 35%.

35%chance of yes

Yes 35%No 65%
Prolepsia forecast made

How Prolepsia reasons

The report Prolepsia wrote with this forecast.

How forecasts are made · Track record

TL;DR

The forecast is 35.4% Yes and 64.6% No. Five or fewer formal Phase 2 references during calendar 2027 is the more likely outcome, but the visible transaction pipeline leaves a substantial chance of exceeding the threshold.

Key evidence

  • Recent formal-reference activity is low. Three 2026 references were verified as of the forecast date: ABF/Hovis on 8 January, Vandemoortele/Délifrance on 22 April, and nexfibre/Substantial on 1 July. These are confirmed entries, not a certified exhaustive annual tally.
  • Referral-specific statistics support a restrained baseline. The CMA’s spreadsheet records seven referrals in April 2024–March 2025, four in April 2025–March 2026, and two in April–September 2026. These are financial-year reporting periods, not interchangeable calendar-year observations (merger outcomes).
  • Policy favors resolving suitable cases earlier. The CMA’s plan emphasizes targeted review, earlier remedies engagement, and potentially waiting for overseas proceedings to resolve UK concerns. That puts downward pressure on references without removing the need for in-depth investigations (annual plan).
  • The pipeline is real, but conditional. AkzoNobel/Axalta’s 11 November 2026 decision remained subject to acceptable undertakings, rather than constituting a formal reference (case record). FirstCash/Ramsdens has a 22 December 2026 Phase 1 deadline, while NRG/Specialist Fleet Services has a 6 January 2027 deadline, creating opportunities for references around the year boundary (FirstCash; NRG).

Uncertainties

The largest unknown is the number and competitive character of transactions reaching the CMA during 2027. A cluster of difficult mergers could lift references above five even without a change in enforcement policy. Conversely, accepted Phase 1 remedies or abandoned deals could shrink the pipeline.

Historical measurement also needs care. The annual overview reports 10 Phase 2 investigations for 2023, five for 2024, and four for 2025, but does not establish an unambiguous effective-reference-date series (annual overview). Resolution depends on individual formal reference dates—not investigation completions, conditional announcements, or generic case-status labels.

Read the full report

TL;DR

The forecast is 35.4% Yes and 64.6% No. Five or fewer qualifying Phase 2 merger references in calendar 2027 is the more likely outcome. The decisive distinction is between a visible pipeline of competition concerns and actual formal references: remedies and year-end timing separate the two.

Context

The question counts distinct merger transactions formally referred for an in-depth investigation between 1 January and 31 December 2027. Exactly five resolves No; six or more resolves Yes. The effective reference date controls. An investigation started earlier and completed in 2027 does not count, while a late-2026 Phase 1 case formally referred in 2027 does. The authoritative record is the CMA’s individual case documentation, available through its merger case register.

As of 16 November 2026, the evidence points to restrained recent referral activity, alongside a meaningful pipeline. The CMA’s stated approach is targeted and proportionate, with greater emphasis on resolving suitable concerns earlier. That supports No as the leading outcome, but it does not impose a ceiling on the number of difficult mergers that can reach Phase 2 (annual report; annual plan).

Evidence

The historical backbone cuts in two directions. More than five annual referrals is common in the longer record. Recent reporting periods are much quieter. The full referral history supplied by the CMA’s spreadsheet is below. These are financial years, except for the final partial period; they are context for the calendar-year question, not substitutes for its counting window (official spreadsheet).

Reporting period Referrals
2003–04 9
2004–05 18
2005–06 17
2006–07 13
2007–08 10
2008–09 8
2009–10 7
2010–11 8
2011–12 9
2012–13 14
2013–14 8
2014–15 6
2015–16 11
2016–17 5
2017–18 9
2018–19 11
2019–20 13
2020–21 9
2021–22 10
2022–23 14
2023–24 3
2024–25 7
2025–26 4
April–September 2026 2

The older record establishes that six references is not an exceptional workload. But it is a poor guide if treated as a stable annual rate. The recent sequence includes three, seven, and four referrals across full financial years, followed by two in the latest half-year. It supports continued variation, not an automatic return to earlier levels (merger outcomes).

Calendar-year evidence requires more care. The annual overview reports the following figures, but its allocation convention is not sufficiently clear to identify them with formal references effective in each year (annual overview).

Calendar year Phase 1 investigations Reported Phase 2 investigations
2023 56 10
2024 38 5
2025 39 4

A case-date reconstruction gives a different history: eight references in 2021, thirteen in 2022, five in 2023, eight in 2024, three in 2025, and three identified through 16 November 2026. The 2021 and 2022 figures each include one Secretary of State public-interest reference. These counts carry coverage and classification limits, so the disagreement with the overview remains a measurement uncertainty rather than a clean correction to every published total (case register).

The strongest recent evidence is the set of individually dated cases. The three identified 2025 starts were Aramark/Entier on 5 August, Constellation/ABVR on 13 October, and Getty Images/Shutterstock on 3 November. Later work on those investigations does not turn them into new starts (Aramark; Constellation; Getty).

For 2026, the verified entries are ABF/Hovis on 8 January, Vandemoortele/Délifrance on 22 April, and nexfibre/Substantial on 1 July. These establish that those references happened; they do not establish a certified exhaustive tally for the year. Further references remained possible after the forecast date (ABF; Vandemoortele; nexfibre).

Policy provides a reason to give the quieter recent period substantial weight. The March 2026 annual plan favors highly targeted reviews, earlier remedies engagement, and waiting for overseas proceedings where those can resolve UK concerns. Remedies guidance effective from 19 December 2025 also widened the circumstances in which behavioural remedies can work, including at Phase 1. I read these as pressure toward fewer references, not as evidence that enforcement has stopped (annual plan; remedies guidance).

There are concrete examples of the distinction. Co-op/Southern Co-op secured undertakings in lieu on 5 November 2026, and Welltower did so on 10 September. Such cases can involve real competition concerns without becoming Phase 2 investigations. Conversely, Vandemoortele shows that an attempted Phase 1 remedy can fail. Earlier engagement creates an exit route, not a guaranteed clearance (Co-op; Welltower; Vandemoortele decision).

The pipeline is the main counterweight. AkzoNobel/Axalta and McCormick/Unilever received conditional referral decisions on 11 November 2026. Both could avoid Phase 2 through acceptable undertakings. Neither announcement is already a qualifying reference (AkzoNobel; McCormick).

Timing makes other cases relevant. FirstCash/Ramsdens has a 22 December 2026 Phase 1 deadline, and NRG/Specialist Fleet Services has a 6 January 2027 deadline. KONE/TK Elevator and OCS/Mitie were at earlier stages without formal Phase 1 timetables on the inspected pages. These provide routes into 2027, but not established findings that Phase 2 is needed (FirstCash; NRG; KONE; OCS).

Sky/ITV adds another possible route. Its public-interest reports are due on 27 January 2027. That deadline is not a Phase 2 reference, and the eventual formal documentation will determine whether an investigation qualifies (Sky/ITV).

Broader deal activity offers only weak support for a rebound. The supplied ONS quarterly totals for completed UK-involving acquisitions are 528 in April–June 2025, 407 in January–March 2026, and 353 in April–June 2026. The figures are provisional, cover transactions worth at least £1 million, and do not match the CMA’s jurisdictional population. They argue against assuming a broad transaction boom, but cannot predict referrals in proportion to deal counts (ONS bulletin).

What's non-obvious

The apparent historical trend depends on what is being counted. An annual total of investigations, a financial-year referral decision, and a calendar-year formal reference are different observations. A busy case register can also contain earlier references, remedy negotiations, or cases whose substantive outcome has already been decided. For this question, a dated formal reference matters more than an “open” label or a competition-concern headline (annual overview; case register).

Policy also works through several channels. Earlier remedies can prevent references, while fast-track procedures can bring a reference forward. Jurisdictional changes exclude some transactions while creating another route to examine others. The sound inference is therefore narrower than “lighter regulation means no Phase 2”: the recent environment favors restraint, but a cluster of difficult deals can still cross the threshold (jurisdiction guide; procedure guidance).

Uncertainties

The largest gap is future transaction flow. The current pipeline cannot reveal how many difficult mergers will emerge during 2027, or how their competitive effects will be distributed. A few additional complex transactions matter greatly when the dividing line is five versus six.

Remedy acceptance is the next key uncertainty. Conditional referral decisions establish unresolved concerns, not the failure of negotiations. Formal undertakings decisions and reference notices will show which pipeline cases actually convert into qualifying starts. Calendar timing adds another layer: negotiations, extensions, and fast-track requests can move an otherwise similar case across year-end (procedure guidance).

Further legislative liberalization is not established. The 22 October 2026 parliamentary answer supplied no introduction timetable for the Competition Reform Bill. Proposed longer remedies windows should therefore not be treated as rules already operating throughout the forecast year (parliamentary answer).

Finally, the historical allocation discrepancy and the completeness of the current reference ledger remain unresolved. A complete, reconciled list of effective formal reference dates would close that gap. These limits weaken confidence in a precise historical baseline, but they do not overturn the conclusion: restrained recent activity makes No more likely, while pipeline conversion and new difficult deals preserve a substantial chance of Yes.

Forecast history

How Prolepsia’s forecast has movedOne forecast so far: 35% on 16 Nov 2026.
DateForecast
35% chance of yes

Sources Prolepsia read

  1. Competition and Markets Authority cases and projects - GOV.UKwww.gov.uk
  2. official spreadsheetassets.publishing.service.gov.uk
  3. Mergers and acquisitions involving UK companies - Office for National Statisticswww.ons.gov.uk
  4. parliamentary answerquestions-statements.parliament.uk
  5. UK Competition Reform Bill faces axe as PM shifts priorities - ION Analyticsionanalytics.com

The question

This question asks whether the United Kingdom's Competition and Markets Authority (CMA) will initiate more than five distinct Phase 2 merger investigations during the 2027 calendar year, from 1 January 2027 through 31 December 2027, inclusive. The question resolves YES if the CMA formally refers at least six distinct mergers for in-depth Phase 2 investigation during this period, and NO if it refers five or fewer. The CMA is the UK's principal competition regulator. Under the UK's merger control regime, the CMA typically conducts an initial Phase 1 investigation to determine whether a proposed or completed merger could substantially lessen competition. Where significant competition concerns remain unresolved, the CMA may refer the merger for an in-depth Phase 2 investigation. Phase 2 investigations involve more detailed scrutiny and can result in unconditional clearance, clearance subject to remedies, prohibition, or other outcomes. As of 16 November 2026, the CMA's official annual merger investigation statistics provide useful historical context. According to its Annual Merger Investigation Outcomes report, updated on 12 October 2026, the CMA investigated 10 mergers at Phase 2 in 2023, five in 2024, and four in 2025. These figures illustrate that the threshold of more than five Phase 2 reviews is meaningful relative to recent activity. The CMA's 2025–2026 annual report also describes its approach to merger enforcement as targeted and proportionate, concentrating on transactions raising significant competition concerns. The forecast concerns new Phase 2 investigations initiated during calendar year 2027, rather than investigations completed during that year. A merger investigated at Phase 1 in 2026 but formally referred to Phase 2 in 2027 will count. Conversely, an investigation referred to Phase 2 in 2026 but continuing into 2027 will not count toward the 2027 total. Primary background sources are the CMA's Annual Merger Investigation Outcomes publication (https://www.gov.uk/government/publications/merger-investigation-outcomes/annual-merger-investigation-outcomes), the CMA's official mergers case register (https://www.gov.uk/cma-cases?case_type=mergers), and its Annual Report and Accounts 2025 to 2026 (https://www.gov.uk/government/publications/cma-annual-report-and-accounts-2025-to-2026/annual-report-and-accounts-2025-to-2026).

How it resolves

The question resolves YES if the UK Competition and Markets Authority formally initiates six or more distinct Phase 2 merger investigations between 1 January 2027 and 31 December 2027, inclusive. It resolves NO if the number of qualifying Phase 2 investigations initiated during that period is five or fewer. A qualifying investigation is a merger inquiry formally referred to an in-depth Phase 2 investigation by the CMA under the applicable UK merger control legislation, principally the Enterprise Act 2002. The relevant date is the effective date of the CMA's formal Phase 2 reference, as recorded in the CMA's official case documentation, rather than the date the merger was first announced, the date Phase 1 commenced, the date a preliminary decision to refer was announced, or the date the Phase 2 investigation concluded. The primary resolution source will be the CMA's official merger case register on GOV.UK and the individual merger inquiry pages, including their statutory timetables, formal reference decisions, and Phase 2 documentation. The CMA's published annual merger investigation statistics and annual reports will serve as supplementary sources for cross-checking the number of qualifying investigations. Where annual aggregate statistics differ from the case-by-case count because of reporting conventions, the count derived from individual formal Phase 2 reference decisions will take precedence. Each distinct merger transaction formally referred to Phase 2 during 2027 will count once, regardless of its eventual outcome. Investigations that subsequently result in clearance, remedies, prohibition, abandonment, or cancellation will remain counted if the formal Phase 2 reference occurred during 2027. Multiple procedural steps, extensions, supplementary reports, or reconsiderations relating to the same merger transaction will not create additional counts unless the CMA formally initiates a genuinely separate Phase 2 investigation concerning a distinct merger transaction. A Phase 1 decision stating that a merger will be referred to Phase 2 unless the parties offer acceptable undertakings will not itself count as a Phase 2 investigation. If the CMA subsequently accepts undertakings in lieu of a reference, the merger will not count. A merger will count only once a formal Phase 2 reference has actually been made. The final count will be determined after the end of 2027, allowing until 31 March 2028 for the CMA to publish or update relevant case documentation. Formal reference decisions issued during 2027 but published subsequently will count according to their effective reference dates. If the official record remains incomplete at the verification deadline, the question will resolve using the available authoritative documentation, provided the evidence is sufficient to determine whether the threshold was exceeded. If at least six qualifying investigations can be verified, the question resolves YES even if other cases remain uncertain. If the threshold cannot be established reliably because essential information is unavailable, the question will be annulled rather than assigned an unsupported outcome. Official CMA records will take precedence over media reports, legal commentary, and third-party databases. Secondary sources may be consulted to identify potentially missing cases but will not override authoritative CMA documentation.

Fine print

The reporting period is the calendar year 2027, not the UK financial year 2027–2028 or the CMA's internal annual reporting period. Dates will be interpreted using UK local time. The question concerns the number of formal Phase 2 merger references, not the number of merger notifications, Phase 1 investigations, preliminary competition concerns, completed Phase 2 reviews, or mergers prohibited by the CMA. Only merger investigations conducted by the UK CMA will qualify. Investigations conducted exclusively by other regulators, including the European Commission, the US Federal Trade Commission, or national competition authorities outside the UK, will be excluded. References involving mergers between non-UK companies will nevertheless count if they are formally referred to Phase 2 by the CMA under its UK merger control jurisdiction. If the CMA's merger review procedures or governing legislation change during 2027, investigations conducted under a legally equivalent successor procedure will count if they clearly represent the formal commencement of an in-depth, second-stage merger investigation. Investigations under unrelated regulatory regimes, including market investigations and digital markets enforcement proceedings, will not count. If the CMA is reorganized, renamed, or replaced during 2027, formal Phase 2 merger investigations initiated by its direct statutory successor will count, provided the successor exercises substantially equivalent UK merger review powers. The threshold remains strictly greater than five: exactly five qualifying investigations resolves NO, while six or more resolves YES.